13D/G large-stake feed

Latest 13D/G Reports

Since 06 May 2026. Review filer CIK, subject security, ownership %, and SEC evidence first.

Recent 13D/G signals

Large-stake disclosures to inspect

Start with holder, issuer/security, stake size, and SEC evidence.

13G/A

PERCEPTIVE ADVISORS LLC stake in PALISADE BIO, INC.

Holder CIK 0001224962

13G/A IMVIQ
CIK
0001224962
Issuer
PALISADE BIO, INC.
Security
IMVIQ
Source
SEC 13G/A
Action
Beneficial ownership disclosure
Magnitude
7.9% / 14,113,863 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

13G/A

PERCEPTIVE ADVISORS LLC stake in RHYTHM PHARMACEUTICALS, INC.

Holder CIK 0001224962

13G/A RYTM
CIK
0001224962
Issuer
RHYTHM PHARMACEUTICALS, INC.
Security
RYTM
Source
SEC 13G/A
Action
Beneficial ownership disclosure
Magnitude
5.1% / 3,519,626 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

13G/A

PERCEPTIVE ADVISORS LLC stake in Traws Pharma, Inc.

Holder CIK 0001224962

13G/A TRAW
CIK
0001224962
Issuer
Traws Pharma, Inc.
Security
TRAW
Source
SEC 13G/A
Action
Beneficial ownership disclosure
Magnitude
6.1% / 979,815 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

13G/A

PERCEPTIVE ADVISORS LLC stake in Amylyx Pharmaceuticals, Inc.

Holder CIK 0001224962

13G/A AMLX
CIK
0001224962
Issuer
Amylyx Pharmaceuticals, Inc.
Security
AMLX
Source
SEC 13G/A
Action
Beneficial ownership disclosure
Magnitude
7.5% / 8,284,882 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

13G

Flagship Pioneering, LLC stake in Generate Biomedicines, Inc.

Holder CIK 0001400240

13G GENB
CIK
0001400240
Issuer
Generate Biomedicines, Inc.
Security
GENB
Source
SEC 13G
Action
Beneficial ownership disclosure
Magnitude
49% / 62,701,915 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

13G/A

PERCEPTIVE ADVISORS LLC stake in X4 PHARMACEUTICALS, INC.

Holder CIK 0001224962

13G/A XFOR
CIK
0001224962
Issuer
X4 Pharmaceuticals, Inc
Security
XFOR
Source
SEC 13G/A
Action
Beneficial ownership disclosure
Magnitude
7.3% / 6,889,163 shares
Filed
15 May 2026, 16:00:03 UTC

Check whether this is a new stake, an amended position, or a material ownership change before moving to the issuer page.

Rows shown
1,401-1,450 of 4,126
Per page
50
Current page
29

Schedule 13D/G ownership events

Activist and large-stake radar

Stake size, change direction, reporting filer, issuer, active/passive form type, and SEC evidence.

Visible reports

6

Fresh large-stake filings promoted above the legacy table.

13D/13G mix

0/6

Active-intent candidates versus passive large-stake disclosures.

Largest visible stake

49%

Highest class ownership surfaced in the preview cards.

Newest evidence

15 May 2026

Use recency before treating an old large-stake story as fresh.

Signal checks

13D active-intent check

active/control intent, item text, amendments

13G passive stake check

large passive holder disclosure

Stake change direction

ownership percent and share change

Issuer and owner follow-up

issuer, filer history, insider activity, 13F context

SEC-verifiable Schedule 13D/G path

Open the Schedule 13D/G filing, then cross-check insider and Form 13F evidence.

Large-stake signal

PERCEPTIVE ADVISORS LLC

PALISADE BIO, INC. (IMVIQ)

Schedule 13G/A Ownership 7.9% Filing-backed
CIK
000119312526226570
Source
SEC Schedule 13G/A
Action
Large beneficial ownership stake disclosed
Magnitude
7.9%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

PERCEPTIVE ADVISORS LLC filed Schedule 13G/A for PALISADE BIO, INC. (IMVIQ). Reported class ownership: 7.9%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Large-stake signal

PERCEPTIVE ADVISORS LLC

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Schedule 13G/A Ownership 5.1% Filing-backed
CIK
000119312526226562
Source
SEC Schedule 13G/A
Action
Large stake reduction disclosed
Magnitude
5.1%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

PERCEPTIVE ADVISORS LLC filed Schedule 13G/A for RHYTHM PHARMACEUTICALS, INC. (RYTM). Reported class ownership: 5.1%. Ownership change: -1.7%. Share change: -20%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Large-stake signal

PERCEPTIVE ADVISORS LLC

Traws Pharma, Inc. (TRAW)

Schedule 13G/A Ownership 6.1% Filing-backed
CIK
000119312526226563
Source
SEC Schedule 13G/A
Action
Large stake reduction disclosed
Magnitude
6.1%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

PERCEPTIVE ADVISORS LLC filed Schedule 13G/A for Traws Pharma, Inc. (TRAW). Reported class ownership: 6.1%. Ownership change: -3.9%. Share change: +10%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Large-stake signal

PERCEPTIVE ADVISORS LLC

Amylyx Pharmaceuticals, Inc. (AMLX)

Schedule 13G/A Ownership 7.5% Filing-backed
CIK
000119312526226565
Source
SEC Schedule 13G/A
Action
Large stake reduction disclosed
Magnitude
7.5%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

PERCEPTIVE ADVISORS LLC filed Schedule 13G/A for Amylyx Pharmaceuticals, Inc. (AMLX). Reported class ownership: 7.5%. Ownership change: -0.7%. Share change: -7.5%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Large-stake signal

Flagship Pioneering, LLC

Generate Biomedicines, Inc. (GENB)

Schedule 13G Ownership 49% Filing-backed
CIK
000119312526226574
Source
SEC Schedule 13G
Action
Large beneficial ownership stake disclosed
Magnitude
49%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

Flagship Pioneering, LLC filed Schedule 13G for Generate Biomedicines, Inc. (GENB). Reported class ownership: 49%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Large-stake signal

PERCEPTIVE ADVISORS LLC

X4 PHARMACEUTICALS, INC. (XFOR)

Schedule 13G/A Ownership 7.3% Filing-backed
CIK
000119312526226568
Source
SEC Schedule 13G/A
Action
Large beneficial ownership stake disclosed
Magnitude
7.3%
Filed
15 May 2026, 16:00:03 UTC
Period
31 Mar 2026

PERCEPTIVE ADVISORS LLC filed Schedule 13G/A for X4 PHARMACEUTICALS, INC. (XFOR). Reported class ownership: 7.3%. Open the SEC evidence before treating this as an activist or passive large-stake signal.

Create an account from this card and we will save this large-stake filer to your watchlist after sign-in or verification.

Filed by Symbol Subject Shares owned Ownership % Source
PERCEPTIVE ADVISORS LLC CIK 0001224962 IMVIQ PALISADE BIO, INC. 14,113,863 7.9% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 RYTM RHYTHM PHARMACEUTICALS, INC. 3,519,626 5.1% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 TRAW Traws Pharma, Inc. 979,815 6.1% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 AMLX Amylyx Pharmaceuticals, Inc. 8,284,882 7.5% SEC filing
Flagship Pioneering, LLC CIK 0001400240 GENB Generate Biomedicines, Inc. 62,701,915 49% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 XFOR X4 PHARMACEUTICALS, INC. 6,889,163 7.3% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 NVNO enVVeno Medical Corporation 68,525 10% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 SABS SAB BIOTHERAPEUTICS, INC. 6,431,743 8.4% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 ALDX Aldeyra Therapeutics, Inc. 0 0% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 TENX Tenax Therapeutics, Inc. 1,447,782 5.5% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 IKT INHIBIKASE THERAPEUTICS, INC. 12,635,875 8.9% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 IRD Opus Genetics, Inc. 8,830,145 10% SEC filing
PERCEPTIVE ADVISORS LLC CIK 0001224962 CTMX CytomX Therapeutics, Inc. 10,098,824 4.6% SEC filing
ATW Partners Opportunities Management, LLC CIK 0001947975 WKHS Workhorse Group Inc. 545,863 5% SEC filing
LAZARD ASSET MANAGEMENT LLC CIK 0001207017 ARCO Arcos Dorados Holdings Inc 23,174,841 18% SEC filing
LAZARD ASSET MANAGEMENT LLC CIK 0001207017 BRSL Brightstar Lottery PLC 9,060,606 4.9% SEC filing
MACKENZIE FINANCIAL CORP CIK 0000919859 CSIQ Canadian Solar Inc. 4,616,690 6.9% SEC filing
Anson Funds Management LP CIK 0001491072 ZNB Zeta Network Group 185,146 8.2% SEC filing
ATW Partners Opportunities Management, LLC CIK 0001947975 FLD Fold Holdings, Inc. 1,739,130 3.3% SEC filing
EARNEST PARTNERS LLC CIK 0001102578 NSP INSPERITY, INC. 2,066,472 5.4% SEC filing
DORFMAN JONATHAN H CIK 0002132108 QVCGA QVC Group, Inc. 655,300 8.1% SEC filing
DISCIPLINED GROWTH INVESTORS INC /MN CIK 0001050442 AIOT Powerfleet, Inc. 7,316,172 5.5% SEC filing
DORFMAN JONATHAN H CIK 0002132108 QVCGA QVC Group, Inc. 415,250 5.2% SEC filing
Lim Chun Yen CIK 0001684034 GIBO GIBO HOLDINGS Ltd 2,371,870 3.6% SEC filing
CADIAN CAPITAL MANAGEMENT, LP CIK 0001423686 FLYW Flywire Corporation 6,618,119 5.5% SEC filing
BANK OF AMERICA CORP /DE/ CIK 0000070858 NTST NETSTREIT Corp. 5,646,241 5.8% SEC filing
EARNEST PARTNERS LLC CIK 0001102578 DAKT DAKTRONICS INC /SD/ 3,190,377 6.6% SEC filing
Caddis Holdings, LP CIK 0002123470 FRMI Fermi Inc. 57,446,450 9.1% SEC filing
Auctus Fund Management LLC CIK 0001700205 BRTX BioRestorative Therapies, Inc. 2,699,470 9.9% SEC filing
Paes-Braga Brian CIK 0002122616 TMCR Metals Royalty Co Inc. 13,972,630 25% SEC filing
EARNEST PARTNERS LLC CIK 0001102578 FORM FORMFACTOR INC 4,875,165 6.3% SEC filing
RP Investment Advisors LP CIK 0001767393 SAAQ Space Asset Acquisition Corp. 1,821,346 7.7% SEC filing
MACKENZIE FINANCIAL CORP CIK 0000919859 CUSIP 805112109 Savaria Corp 2,949,000 4.1% SEC filing
EARNEST PARTNERS LLC CIK 0001102578 GATX GATX CORP 2,606,241 7.3% SEC filing
Bloom Brian Matthew CIK 0002120718 MSLE Satellos Bioscience Inc. 1,133,401 7.4% SEC filing
MAK Capital Fund LP CIK 0001426156 AUTL Autolus Therapeutics plc 33,621,487 13% SEC filing
Jeito II S.L.P. CIK 0002134396 ODTX ODYSSEY THERAPEUTICS, INC. 3,690,145 7.8% SEC filing
ACORN BIOVENTURES, L.P. CIK 0001766853 KPTI Karyopharm Therapeutics Inc. 1,518,113 6.7% SEC filing
First Trust Capital Management L.P. CIK 0001604488 RAC Rithm Acquisition Corp. 363,144 1.5% SEC filing
BROWN ADVISORY INC CIK 0001345929 ESTA Establishment Labs Holdings Inc. 1,578,119 5.4% SEC filing
Palisades Goldcorp Ltd. CIK 0001791972 NFGC New Found Gold Corp. 26,750,000 7.8% SEC filing
Ugwumba Chidozie CIK 0001835544 CLNN Clene Inc. 1,351,071 9.7% SEC filing
Anson Funds Management LP CIK 0001491072 IMPP Imperial Petroleum Inc. 3,466,680 7.8% SEC filing
BROWN ADVISORY INC CIK 0001345929 ANDG Andersen Group Inc. 2,516,555 20% SEC filing
MACKENZIE FINANCIAL CORP CIK 0000919859 HCSG HEALTHCARE SERVICES GROUP INC 2,672,214 3.8% SEC filing
Marex Financial CIK 0002088488 TWG Top Wealth Group Holding Ltd 54,776 9.4% SEC filing
Anson Funds Management LP CIK 0001491072 LAES SEALSQ Corp 12,457,698 5.6% SEC filing
ASKELADDEN CAPITAL MANAGEMENT LLC CIK 0001815572 CRMT AMERICAS CARMART INC 438,789 5.3% SEC filing
Bellevue Group AG CIK 0001674546 VRDN Viridian Therapeutics, Inc. 6,726,144 6.6% SEC filing
Bellevue Group AG CIK 0001674546 CLDX Celldex Therapeutics, Inc. 1,200,000 1.5% SEC filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .